This volume presents the entire breadth of translational cancer research and brings together members of academia and industry in the expectation of accelerating interactions and progress in the field. A variety of key topics are presented, beginning with discovery of molecular targets and pathways (oncogene, cell survival, tumor suppression, cell death), host-neoplasm interactions (cell adhesion, matrix proteases), early detection, monitoring progression, understanding tumor progression and metastasis, immune surveillance, in vivo molecular imaging, animal models, drug discovery including chemistry, high-throughput assays, mechanism determination, target validation, therapeutic window and some progress in clinical trials for more advanced agents and targets.

This book offers significant coverage on different aspects of cancer from risk factors to the mechanisms leading to tumor progression and metastasis. Although tremendous progress has been made in cancer research and treatment, cancer metastasis remains a major unmet clinical need. The life and death of many cancer patients hangs on the degree of metastasis. This book provides new perspectives for diagnosis and cancer therapy. It includes new technologies and a new basis for current cancer therapies. To guarantee the high quality of this book, important topics are included and rigorously discussed in a simple and authentic way. The book addresses important challenges governing tumor progression and metastasis and brings new responses to both diagnosis and therapy. This book is a great source of knowledge and will be useful for researchers, medical doctors, oncologists, graduate and medical students, continued medical educators, health care providers, and all individuals interested in understanding cancer and its challenges.

Hypoxia, defined as reduced oxygen tension, is a common physiological phenomenon in both normal embryonic development and malignancy progression. Although severe hypoxia is generally toxic for both normal tissue and tumors, neoplastic cells gradually adapt to prolonged hypoxia though additional genetic and genomic changes with a net result that hypoxia promotes tumor progression and therapeutic resistance. Hypoxia promotes cancer progression by regulating various aspects of cancer biology, including radiotherapy resistance, metabolism, angiogenesis and invasion/migration

Programmed cell death (PCD) plays pivotal roles in tumor progression, cancer therapeutics and resistance of tumor cells to therapy. This book examines the mechanisms involved in mediating and regulating PCD in cancer. It also provides a detailed indication of the utility of PCD in cancer therapy. The book features chapters on the current and future of RNA interference in therapeutics and Pathways involved in Stem Cell Survival and Death.

Prostate cancer (PCa) is among the most diagnosed cancers in men worldwide as well as one of the most common causes of cancer-related deaths. Despite the advances in treatment, the disease remains associated with poor survival and resistance to cytotoxic and targeted therapies. Therapy Resistance in Prostate Cancer: Mechanisms and Insights highlights the main mechanisms that are responsible for therapy resistance in PCa allowing researchers and clinicians to have a synopsis of current options and new therapies that can be proposed to overcome this resistance. Understanding the mechanisms responsible for chemotherapy resistance helps researchers all over the world to delve deeper into the pathways behind this resistance and potentially discover new therapeutic targets for PCa. Tackles the topic of resistance from a broader perspective, including, but not limited to, the role of the extracellular matrix and cancer stem cells in therapy resistance Creates understanding on how to develop novel therapies that specifically target CSCs to eliminate the regenerating capacity of the tumor and overcome therapy resistance Helps in identifying novel molecular biomarkers and potential therapeutic targets pertaining to the tumor microenvironment to overcome therapy resistance Provides a general view of the main pathways involved in PCa progression that will aid in understanding the mechanisms responsible for chemotherapy resistance

Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.